Search Results - david+kass

6 Results

Sort By:

Non-invasive Left Ventricular End Diastolic Pressure (LVEDP) Measurement for In-hospital, Outpatient and Home Diagnostic Monitoring

Unmet NeedBoth physicians and surgeons rely heavily on the cardiac chamber pressures, especially that in the left ventricle, to assess the fluid volume status of patients and heart function pre and post procedures in the in-hospital setting, outpatient clinics or when patients are at their home. Current methodologies are either invasive in nature with...

Published: 3/13/2025 | Inventor(s): Soumyadipta Acharya, Nichaluk Leartprapun, Qian Liu, Jackline Wanjala, Brian Bernier, Trent Langston, Viachaslau Barodka, David Kass, Majd AlGhatrif, Umang Anand, Chao-Wei Hwang, Peter Johnston, Andrew Bicek

Keywords(s): Clinical Diagnostics, Diagnostic Tool, Measurement Tool

Category(s): Technology Classifications > Diagnostics > In Vivo Diagnostics, Technology Classifications > Diagnostics

New Method of mTOR Regulation by TSC2 Modification

Unmet NeedImmunotherapies that boost T cell responses have demonstrated therapeutic efficacy in numerous cancers. To improve the efficacy and expand the clinical utility of immunotherapy, improved methods of stimulating T cell responses are needed. mTORC1 is a critical regulator of T cell activation, differentiation and function. While modulating mTORC1...

Published: 3/13/2025 | Inventor(s): David Kass, Mark Ranek, Kristen Kokkonen, Jonathan Powell, Chirag Patel

Keywords(s): Cancers, Cell Therapy/Gene Therapy, Combination, Disease Indication, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities

Targeting TSC2 S1366 (mouse, rat) S1365 (human) by gene engineering or phosphorylation to Regulate mTOR Signaling Cascades for Therapeutic Indications

Unmet NeedThe mechanistic target of rapamycin complex-1 (mTORC1) coordinates cellular processes and regulates recycling pathways in order to control cell growth and metabolic homeostasis. Additionally, in immune cells when the T-cell receptor is activated, the mTORC1 signaling pathway is also engaged and thus plays an important role in T-cell activation,...

Published: 3/14/2025 | Inventor(s): David Kass, Kristen Kokkonen, Brittany Dunkerly-Eyring, Mark Ranek

Keywords(s): Disease Indication, Inflammatory Disorders, Target, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Targets

Treatment of Post-menopausal Obesity and Associated Disease by PDE9 Inhibitors

Unmet NeedObesity is a serious health problem both globally and in the United States. Obesity is associated with numerous comorbidities including type-2 diabetes, cardiovascular disease, and certain types of cancers. In particular, obesity is commonly seen in the post-menopausal population as 74% of American women over the age of 60 are considered overweight....

Published: 3/14/2025 | Inventor(s): David Kass, Dong Ik Lee, Sumita Mishra

Keywords(s): Antagonists/Inhibitors, Disease Indication, Metabolic Disorders, Obesity, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Obesity

Method to Improve Heart Failure by Restoration of Synchronous Contraction after Period of Dyssynchrony

C11275: Novel Method to Restore Synchronous Contraction in Heart FailureNovelty: This technology provides a pharmacological approach to mimic Cardiac Resynchronization Therapy (CRT) without artificial electric stimulation.Value Proposition: This invention provides potential improvement in heart failure patients whose hearts are synchronous or dyssynchronous....

Published: 3/13/2025 | Inventor(s): David Kass, Jonathan Kirk, Gordon Tomaselli

Keywords(s): Cardiovascular Diseases, Congestive Heart Failure, Congestive Heart Failure (CHF), Disease Indication, Electrical Stimulation Device, Implanted Device, Implants, Therapeutic Devices, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular > Congestive Heart Failure, Technology Classifications > Medical Devices > Therapeutic Devices, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Medical Devices

Novel Compounds targeting GAPDH-Siah Cell Death Cascade

Novel Compounds targeting GAPDH-Siah Cell Death Cascade JHU Ref #: C11114 Value Proposition Targeted therapy: Small molecule compound that inhibits the GAPDH-Siah cell cascade to prevent cell death in degenerative diseases Broad Application: Effective across stress-mediated conditions, including Alzheimer’s, Parkinson’s, stroke,...

Published: 3/13/2025 | Inventor(s): Neelam Shahani, Toshiaki Saito, David Kass, Eiki Takimoto, Akira Sawa

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, Biomarker, CNS and Neurological Disorders, Disease Indication, Huntington's Disease, Mechanism of Action Biomarker, Neurodegenerative Diseases, Non-novel, Novel, Predicted Novelty, Psychiatric Diseases, Repurposed, Schizophrenia, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Psychiatry > Schizophrenia, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Psychiatry, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Huntington's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease